Cardiovascular biomarkers of response to accelerated low frequency repetitive transcranial magnetic stimulation in major depression

Background and objective: Repetitive transcranial magnetic stimulation (rTMS) is an effective and safe treatment for major depressive disorder (MDD). rTMS is in need of a reliable biomarker of treatment response. High frequency (HF) dorsolateral prefrontal cortex (DLPFC) rTMS has been reported to induce significant changes in the cardiac activity of MDD patients. Low frequency DLPFC rTMS has many advantages over HF-DLPFC rTMS and thus this study aims to further investigate the effect of low frequency 1 Hz right hemisphere (R)-DLPFC rTMS on the cardiac activity of MDD patients, as well as the potential of using electrocardiogram (ECG) parameters as biomarkers of treatment outcome. Methods: Baseline ECG sessions were performed for 19 MDD patients. All patients then underwent 40 sessions of accelerated 1 Hz R-DLPFC rTMS one week after the baseline session. Results: Heart rate (HR) significantly decreased from the resting period to the first and third minute of the 1 Hz R-DLPFC rTMS period. Resting HR was found to have a significant negative association with treatment outcome. Prior to Bonferroni correction, HR during stimulation and the degree of rTMS-induced HR reduction were significantly negatively associated with treatment outcome. No significant changes were observed for the heart rate variability (HRV) parameters. Limitations: Sample size (n = 19); the use of electroencephalography equipment for ECG; lack of respiration monitoring; relatively short recording duration for HRV parameters. Conclusion: This novel study provides further preliminary evidence that ECG may be utilized as a biomarker of rTMS treatment response in MDD.

Automated summary

This study investigated the effect of low frequency right hemisphere dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation (rTMS) on the cardiac activity of major depressive disorder (MDD) patients. The results showed a significant decrease in heart rate during rTMS and a negative correlation between resting heart rate and treatment outcome. The study provides preliminary evidence that electrocardiogram (ECG) may be used as a biomarker of rTMS treatment response in MDD.